Tip Sheet: Soy-Based Mostly Natural S-equol Suppleme
Four clinical studies that add to the evidence about the use of a brand new nutritional supplement containing the whole soy germ-based ingredient Pure S-equol to improve well being have been presented on the North American Menopause Society (NAMS) Annual Meeting. These research include a poster about a first-of-its-kind examine in U.S. girls that documents the effectiveness of Natural S-equol in decreasing the frequency of average to extreme scorching flashes and reducing muscle and joint pain. A second poster reported the primary clinical research about Pure S-equol contributions to bone health. Further studies examined the supplement’s effect on “bad” LDL-cholesterol and its safety. The findings are summarized beneath. Additional information about Natural S-equol, including how it is made, is at www.naturalequol.com. The data will probably be introduced within the Poster Session, Thursday, Oct. 7, 2010 5:15 PM CDT (6:15 PM EDT). Natural S-equol Supplement Reduces Menopausal Scorching Flashes in U.S. Ladies
Eight weeks of day by day doses of a complete soy germ -based mostly complement containing Pure S-equol were better or just like daily doses of soy isoflavones in reducing the frequency of average to extreme sizzling flashes, in the primary comparability examine of its type among U.S. postmenopausal girls. Extra women taking Pure S-equol achieved a 50 % or more reduction of their average daily scorching flash frequency than these receiving the isoflavones. Moreover, muscle and joint pain decreased more for those taking Pure S-equol in comparison with these taking the isoflavones.
Poster P-22
Efficacy and security of natural S-equol supplement in US postmenopausal women.
Belinda H. Jenks of Scientific Affairs, Pharmavite LLC, Northridge, CA, et.al. Natural S-equol Inhibits Bone Break Down, Prevents Bone Mineral Density Loss
In the first examine to doc proof in postmenopausal Japanese women that the Pure S-equol complement given for 12 months considerably inhibited bone break down, or resorption, the supplement also significantly prevented a lower in whole physique bone mineral density, in comparison with a placebo.
Poster P-seventy nine
Impact of pure S-equol on bone metabolism in equol non-producing postmenopausal Japanese girls: a pilot randomized placebo-controlled trial.
Tomomi Ueno of Saga Nutraceutricals Analysis Institute, Otsuka Pharmaceutical Co., Ltd., Japan, et.al. Pure S-equol Lowers “Bad” LDL-Cholesterol in the Obese
After three months of daily doses of the Pure S-equol supplement, obese Japanese grownup women and men significantly lowered their blood levels of “bad” low-density lipoprotein (LDL), in comparison with those receiving a placebo.
Poster P-78
The impact of equol on obesity and metabolic syndrome in Japanese, from the standpoint of gender and equol producing functionality.
Shigeto Uchiyama of Saga Nutraceuticals Research Institute, Otsuka Pharmaceutical Co., Ltd., Japan, et. al. Security Knowledge from 12-Week Examine of Pure S-equol Use in Japanese Ladies
Investigators identified no security issues or severe antagonistic occasions, notably in the female reproductive system, among wholesome Japanese postmenopausal girls who took each day doses of the Natural S-equol supplement for 12 weeks, in comparison with these receiving a placebo. The investigators discovered no abnormal modifications in blood concentrations of five hormones when measured at the research begin and at weeks 4, eight and 12 of the study. Additionally, ultrasound measures of the thickness of the lining of the uterus and cellular research of the tissue lining the vagina recognized no biological effects of the supplement on the women’s reproductive organs. Moreover, mammography outcomes documented no differences among the girls.
Poster P-46
Japan security assessments of natural S-equol supplement by consecutive ingestion to postmenopausal Japanese women.
Ayuko Oyama of Saga Nutraceuticals Analysis Institute, Otsuka Pharmaceutical Co., Ltd., Japan, et. al. ###
About Pure S-equol S-equol is a compound resulting — when certain bacteria are present in the digestive tract — from the pure metabolism, or conversion, of daidzein, an isoflavone found in complete soybeans. Not everybody can produce S-equol after soy consumption, as the manufacturing relies on the varieties of micro organism present in the massive intestine and could also be influenced by the quantity of soy consumed. About 50 % of Asians and 20 to 30 percent of North Individuals and Europeans, who generally eat much less soy than Asians, have the power to produce S-equol. Analysis signifies that Japanese girls have documented milder menopausal symptoms in these who’re S-equol producers in comparison with nonproducers. Also, previous clinical trials have documented the effectiveness of Pure S-equol to manage menopausal signs in Japanese women who’re S-equol nonproducers. S-equol selectively binds to the receptors for the naturally occurring feminine intercourse hormone estrogen, with a strong affinity to the estrogen receptor beta. On binding to these receptors, S-equol mimics some, but not all, activities of natural estrogen. Because of these actions on the receptor, it has been proposed that S-equol might alleviate a few of the symptoms caused by diminished estrogen production during menopause. How SE5-OH is Made All four studies offered at NAMS used complement tablets that contained Natural S-equol. The SE5-OH is the product of fermentation of entire soy germ by the bacterial strain Lactococcus 20-ninety two using a patented and proprietary process by the Otsuka Pharmaceutical Co., Ltd. The process results in the conversion of the daidzein to S-equol. SE5-OH is created beneath present Good Manufacturing Practices. Following fermentation, the micro organism undergo heat denaturation and are deactivated. The process is designed to produce a Natural S-equol wealthy product, or nutraceutical ingredient. The ingredient has self-affirmed GRAS (Usually Acknowledged As Protected) status. Growth and ongoing analysis of SE5-OH containing Natural S-equol is performed by the Saga Nutraceuticals Research Institute of Otsuka Pharmaceutical Co., Ltd. Pharmavite LLC, the makers of Nature Made® vitamins and minerals and a subsidiary of Otsuka, is learning SE5-OH containing Natural S-equol in supplement form for the management of menopausal symptoms. About Pharmavite LLC: For almost 40 years, Pharmavite has earned and maintained the trust of healthcare professionals, consumers, and retailers by manufacturing excessive-high quality vitamins, minerals, herbs and other dietary supplements that are protected, effective and science-based. Nature Made® is the primary selling dietary supplement brand within the meals, drug, membership and mass channels. The dietary supplement business is regulated by the U.S. Food and Drug Administration and the Federal Commerce Fee, in addition to by government businesses in every of the 50 states. About Otsuka Pharmaceutical Co., Ltd.: Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a worldwide healthcare company with the company philosophy: ‘Otsuka-folks creating new merchandise for better well being worldwide.’ Otsuka researches, develops, manufactures and markets progressive and authentic merchandise, with a concentrate on pharmaceutical products for the therapy of diseases and shopper products for the maintenance of on a regular basis health. Otsuka is committed to being a corporation that creates world value, adhering to the high ethical standards required of an organization involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural surroundings. Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding firm for the Otsuka Group. The Otsuka Group comprises 145 firms and 更年期（及び更年期 サプリ） employs approximately 39,000 individuals in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥1,084.2 billion (approx. US $11.7 billion*) in annual revenues in fiscal 2009. Go to Otsuka Pharmaceutical Co., Ltd.
